Alembic receives USFDA final approval for Nifedipine Extended-Release Tablets
Nifedipine Extended-Release Tablets have an estimated market size of US $56 million for twelve months ending September 2022
Nifedipine Extended-Release Tablets have an estimated market size of US $56 million for twelve months ending September 2022
The show will be a part of the India Pharma Week, a marquee celebration catering to every need of the pharma community attendees
Cyclophosphamide Capsules, 25 mg and 50 mg, have an estimated market size of US$ 8 million for twelve months ending Sep 2022 according to IQVIA.
Doxycycline Capsules (RLD Oracea) had estimated annual sales of US $215 million in the US
Drospirenone Tablets (RLD Slynd) had estimated annual sales of US $141 million in the US
Ketorolac Tromethamine is advised for the short-term management of moderately severe acute pain in adult patients
Mesalamine Extended-Release Capsules are indicated for the maintenance of remission of ulcerative colitis in adults.
Through the collaboration, Lonza will gain access to Singzyme’s enzymatic conjugation platform enabling the site-specific binding of payloads with peptidic linkers to proteins of interest
The company has been ranked 8th on the list this year for three key attributes: ‘innovative leader in the industry’, ‘is socially responsible’ and ‘has loyal employees’
This is the first injectable product approval from our General Sterile Facility (F-3) which was inspected in August, 2022.
Subscribe To Our Newsletter & Stay Updated